New Mexico Educational Retirement Board Acquires New Shares in Krystal Biotech, Inc. $KRYS

Posted by Stanley Muller on Nov 12th, 2026

New Mexico Educational Retirement Board acquired a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 5,500 shares of the company’s stock, valued at approximately $1,829,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in KRYS. Jacobi Capital Management LLC bought a new stake in shares of Krystal Biotech in the third quarter worth $56,000. New York Life Investment Management LLC increased its stake in shares of Krystal Biotech by 10.4% in the 3rd quarter. New York Life Investment Management LLC now owns 3,497 shares of the company’s stock worth $1,163,000 after purchasing an additional 330 shares in the last quarter. Retirement Systems of Alabama purchased a new stake in shares of Krystal Biotech in the 3rd quarter worth $9,137,000. Allspring Global Investments Holdings LLC raised its holdings in Krystal Biotech by 4.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 54,625 shares of the company’s stock worth $17,770,000 after purchasing an additional 2,218 shares during the period. Finally, Ethic Inc. raised its holdings in Krystal Biotech by 10.7% in the 3rd quarter. Ethic Inc. now owns 1,335 shares of the company’s stock worth $444,000 after purchasing an additional 129 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the transaction, the insider directly owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. This represents a 1.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the transaction, the director directly owned 50,000 shares in the company, valued at $16,456,000. This represents a 33.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 13.10% of the stock is currently owned by company insiders.

Krystal Biotech Trading Up 0.8%

Shares of NASDAQ:KRYS opened at $308.81 on Thursday. The company has a market capitalization of $9.15 billion, a PE ratio of 41.90 and a beta of 0.56. The business’s fifty day simple moving average is $329.35 and its 200-day simple moving average is $309.43. Krystal Biotech, Inc. has a 12-month low of $198.02 and a 12-month high of $382.54.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.26. The business had revenue of $127.34 million for the quarter, compared to analysts’ expectations of $125.77 million. Krystal Biotech had a net margin of 47.91% and a return on equity of 17.02%. Research analysts predict that Krystal Biotech, Inc. will post 7.74 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on KRYS shares. Zacks Research downgraded Krystal Biotech from a “hold” rating to a “strong sell” rating in a research report on Friday, October 23rd. Chardan Capital raised shares of Krystal Biotech to a “strong-buy” rating in a report on Monday, August 3rd. HC Wainwright reiterated a “buy” rating and set a $361.00 price objective on shares of Krystal Biotech in a research report on Thursday, October 15th. Citigroup dropped their target price on Krystal Biotech from $416.00 to $412.00 and set a “buy” rating for the company in a report on Tuesday, November 3rd. Finally, The Goldman Sachs Group started coverage on shares of Krystal Biotech in a report on Thursday, September 24th. They set a “buy” rating and a $441.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Krystal Biotech currently has an average rating of “Moderate Buy” and a consensus price target of $375.00.

Get Our Latest Report on KRYS

Krystal Biotech Company Profile

(Free Report)

Krystal Biotech, Inc. is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients’ cells. Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin’s structure.